- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05160584
재발성 및/또는 불응성 다발성 골수종 환자의 실제 현재 치료 표준에 대한 연구 (MoMMent)
재발성 및/또는 불응성 다발성 골수종 환자의 실생활 현재 치료 표준에 대한 전향적 다국적 연구
The purpose of this study is to assess in real-life clinical practice, over a 24-month period, the effectiveness and safety and patient-reported outcomes (PROs) associated with standard of care (SOC) antimyeloma treatments in participants with previously treated relapsed and/or refractory multiple myeloma.
연구 개요
연구 유형
등록 (실제)
연락처 및 위치
연구 장소
-
-
-
Alexandroupoli, 그리스, 68100
- University Hospital of Alexandroupolis
-
Athens, 그리스, 115 26
- Henry Dunant Hospital Center
-
Athens, 그리스, 115 28
- Alexandra Hospital
-
Athens, 그리스, 115 27
- Laiko General Hospital Of Athens 1
-
Athens, 그리스, 115 27
- Laiko General Hospital of Athens 2
-
Piraeus, 그리스, 18537
- Metaxa Cancer Center Hospital Of Piraeus
-
Rio, 그리스, 265 04
- General University Hospital of Patras
-
Thessaloniki, 그리스, 546 39
- Anticancer Hospital of Thessaloniki Theageneio
-
Thessaloniki, 그리스, 54636
- Ahepa University General Hospital of Thessaloniki
-
-
-
-
-
Amsterdam, 네덜란드, 1081 HV
- VU Medisch Centrum
-
Groningen, 네덜란드, 9713 GZ
- UMCG
-
-
-
-
-
Berin, 독일, 12203
- Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin
-
Cologne, 독일, 50397
- Universitaetsklinikum Koeln
-
Dresden, 독일, 01307
- Universitatsklinikum Carl Gustvav Carus Dresden an der Technischen Universitat Dresden
-
Hamburg, 독일, 20251
- Universitätsklinik Hamburg-Eppendorf - Orthopädische Universitätsklinik und Poliklinik
-
Hamm, 독일, 59073
- St. Barbara-Klinik Hamm GmbH
-
Heidelberg, 독일, 69120
- Universitaetsklinikum Heidelberg
-
Karlsruhe, 독일
- Staedtisches Klinikum Karlsruhe gGmbH
-
Leipzig, 독일, 4103
- Universitaetsklinikum Leipzig
-
Leipzig, 독일, 04103
- MVZ Mitte-Onkologische Schwerpunktpraxis
-
Tübingen, 독일, 72076
- Klinikum der Eberhard Karls Universitaet Abt fur innere Med II Haematologie Onkologie Germany
-
Würzburg, 독일, 97080
- Universitatsklinikum Wurzburg
-
Zwickau, 독일, 08060
- Heinrich-Braun-Klinikum gGmbH
-
-
-
-
-
Bucharest, 루마니아, 022328
- Fundeni Clinical Institute
-
Bucharest, 루마니아
- Spitalul Clinic Coltea, Clinica Hematologie
-
Cluj-Napoca, 루마니아, 400015
- Institutul Oncologic Prof Dr. Ion Chiricuta Cluj Napoca 1
-
-
-
-
-
Edegem, 벨기에, 2650
- UZ Antwerpen
-
Genk, 벨기에, 3600
- Ziekenhuis Oost-Limburg
-
Leuven, 벨기에, 3000
- UZ Leuven
-
Mons, 벨기에, 7000
- Chu Helora Hospital De Mons Site Kennedy
-
Sint-Niklaas, 벨기에, 9100
- Vitaz
-
Yvoir, 벨기에, 5530
- Ucl de Mont-Godinne
-
-
-
-
-
Chur, 스위스, 7000
- Kantonsspital Graubunden
-
Winterthur, 스위스, 8400
- Kantonsspital Winterthur, Medizinische Onkologie
-
Zurich, 스위스, 8091
- Universitatsspital Zurich
-
Zurich, 스위스, 8032
- Hirslanden Klinik Hirslanden
-
-
-
-
-
Barcelona, 스페인, 08908
- Inst. Cat. Doncologia-H Duran I Reynals
-
Gijón, 스페인, 33394
- Hosp. de Cabuenes
-
Granada, 스페인, 18014
- Hosp. Univ. Virgen de Las Nieves
-
Jerez de la Frontera, 스페인, 11407
- Hosp. de Jerez de La Frontera
-
León, 스페인, 24008
- Hosp. de Leon
-
Madrid, 스페인, 28041
- Hosp. Univ. 12 de Octubre
-
Madrid, 스페인, 28034
- Hosp. Univ. Ramon Y Cajal
-
Palma, 스페인, 7120
- Hosp. Univ. Son Espases
-
Pamplona, 스페인, 31008
- Clinica Univ. de Navarra
-
Salamanca, 스페인, 37007
- Hosp Clinico Univ de Salamanca
-
Santander, 스페인, 39008
- Hosp. Univ. Marques de Valdecilla
-
Santiago de Compostela, 스페인, 15706
- Hosp. Clinico Univ. de Santiago
-
Valencia, 스페인, 46010
- Hosp. Clinico Univ. de Valencia
-
Valencia, 스페인, 46017
- Hosp. Univ. Dr. Peset
-
Valladolid, 스페인, 47003
- Hosp. Clinico Univ. de Valladolid
-
Zaragoza, 스페인, 50009
- Hosp. Univ. Miguel Servet
-
-
-
-
-
Bristol, 영국, BS10 5NB
- Southmead Hospital
-
London, 영국, NW1 2PG
- University College Hospital
-
London, 영국, SE5 9RS
- Kings College Hospital
-
London, 영국, SW17 OQT
- St Georges Hospital
-
Maidstone, 영국, ME16 9QQ
- Maidstone Hospital
-
Nottingham, 영국, NG5 1PB
- Nottingham University Hospitals NHS Trust
-
Surrey, 영국, SM2 5PT
- The Royal Marsden NHS Trust Sutton
-
-
-
-
-
Leoben, 오스트리아, 8700
- LKH Leoben
-
Vienna, 오스트리아, 1060
- Krankenhaus der barmherzigen Schwestern
-
-
-
-
-
Bari, 이탈리아, 70124
- U.O. Ematologia Istituto Tumori Giovanni Paolo II
-
Bari, 이탈리아, 70124
- Oncologia Medica - Irccs - Istituto Tumori Giovanni Paolo II
-
Bologna, 이탈리아, 40138
- Istituto di Ematologia Seràgnoli azienda ospedaliera univeristaria Policlinico S.Orsola-Malpighi
-
Catania, 이탈리아, 95128
- Policlinico di Catania
-
Civitanova Marche, 이탈리아, 62012
- Ospedale Civile di Civitanova Marche
-
Genova, 이탈리아, 16132
- Ospedale Policlinico San Martino IRCCS
-
Genova, 이탈리아, 16132
- IRCCS Azienda Ospedaliera San Martino - IST
-
Lecce, 이탈리아, 73100
- Ospedale Vito Fazzi
-
Meldola, 이탈리아, 47014
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
-
Padova, 이탈리아, 35128
- Universita degli Studi di Padova Azienda Ospedaliera di Pa
-
Palermo, 이탈리아, 90146
- Ospedale Villa Sofia-Cervello
-
Pavia, 이탈리아, 27100
- Fondazione IRCCS Policlinico San Matteo
-
Pescara, 이탈리아, 65124
- Presidio Ospedaliero Pescara
-
Reggio Calabria, 이탈리아, 89124
- Grande Ospedale Metropolitano 'Bianchi-Melacrino-Morelli' Reggio Calabria
-
Roma, 이탈리아, 00168
- Fondazione Policlinico Universitario A Gemelli IRCCS
-
Roma, 이탈리아, 128
- Campus Bio Medico di Roma
-
Roma, 이탈리아, 00161
- Università di Roma La Sapienza
-
San Giovanni Rotondo, 이탈리아, 71013
- IRCCS Ospedale Casa Sollievo della Sofferenza
-
San Giovanni Rotondo, 이탈리아, 71013
- Casa Sollievo Della Sofferenza IRCCS
-
Tricase, 이탈리아, 73039
- Ospedale Cardinale G. Panico
-
Vicenza, 이탈리아, 36100
- Azienda Ulss 8 Berica- Ospedale Di Vicenza
-
-
-
-
-
Chaves, 포르투갈, 5400 482
- Ulstmad - Hosp. Chaves
-
Coimbra, 포르투갈, 3004 561
- Uls Coimbra - Hosp. Univ. Coimbra
-
Porto, 포르투갈, 4200 319
- Uls Sao Joao - Hosp. Sao Joao
-
-
-
-
-
Lille, 프랑스, 59037
- CHRU de Lille Hopital Claude Huriez
-
Montpellier, 프랑스, 34295
- CHU de Montpellier Hopital Saint Eloi
-
Nantes, 프랑스, 44093
- CHU de Nantes hotel Dieu
-
Pierre-Bénite, 프랑스, 69495
- Centre hospitalier Lyon-Sud
-
Toulouse, 프랑스, 31059
- Pôle IUC Oncopole CHU
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
The study population consists of participants with previously treated multiple myeloma, having received standard of care (SOC) antimyeloma treatments during local clinical practices.
설명
Inclusion Criteria:
- For Period 1 and 2: Have a documented diagnosis of multiple myeloma according to International myeloma working group (IMWG) diagnostic criteria. For Period 3: Start of talquetamab for the treatment of a documented diagnosis of relapsed and/or refractory multiple myeloma (RRMM) according to IMWG diagnostic criteria and the approved indication. The decision to start talquetamab must be made independently of the decision to participate in the study, with the start of treatment occurring up to 28 days following the start of screening or having occurred up to 21 days before the informed consent form (ICF) date
- For Period 1 and 2: Have an Eastern Cooperative Oncology Group (ECOG) Performance Status grade of 0 or 1. For Period 3: Have ECOG performance status of 0,1 or 2
- For Period 1,2 and 3: Must not be pregnant or must not plan to become pregnant within the study period
- For Period 1,2 and 3: Participants must sign an ICF indicating that he or she understands the purpose and observational nature of the study and is willing to participate. Consent is to be obtained prior to the initiation of any study-related data collection
- For Period 1 and 2: Received at least 3 prior lines of therapy (induction with or without hematopoietic stem cell transplant and with or without maintenance therapy is considered a single regimen). Undergone at least 1 complete cycle of treatment for each line of therapy, unless progressive disease (PD) was the best response to the line of therapy
- For Period 1 and 2: Must have documented evidence of progressive disease based on participating physician's determination of response by the IMWG response criteria on or after the last regimen. Participants with documented evidence of progressive disease within the previous 6 months and who are refractory or non-responsive to their most recent line of treatment afterwards are also eligible
- For Period 1 and 2: Measurable disease at screening as defined by any of the following: Serum monoclonal paraprotein (M-protein) level 1.0 g/dL or urine M-protein level 200 mg/24 hours; or Light chain multiple myeloma without measurable disease in the serum or the urine: Serum immunoglobulin free light chain 10 mg/dL and abnormal serum immunoglobulin kappa lambda free light chain ratio
- Period 1: Received as part of previous therapy a PI, an IMiD, and an anti-CD38 antibody (prior exposure can be from different monotherapy or combination regimens)
- Period 2: Received as part of previous therapy a PI, an IMiD, an anti-CD38 antibody, and BCMA-targeted therapy (prior exposure can be from different monotherapy or combination regimens)
- For period 3: At least one of the following prior to the start of talquetamab: a. Measurable disease at screening as defined by any of the following: Serum monoclonal paraprotein (M-protein) level greater than or equal to (>=) 0.5 grams per deciliter (g/dL) or urine M-protein level >= 200 milligram (mg) /24 hours; or b. serum immunoglobulin free light chain >= 10 milligrams per deciliter (mg/dL) and abnormal ratio of involved and uninvolved free light chains or c. presence of bone lesions or plasmacytomas (>=1 lesion has 2 diameters >= 1 centimeter [cm])
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: PROSPECTIVE
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
Participants with Relapsed/Refractory Multiple Myeloma
Participants with relapsed/refractory multiple myeloma (RRMM) receiving antimyeloma treatment as standard of care (SOC) under routine clinical practice will be observed. The primary data source will be medical records of each participant. |
There is no interventional treatment component for participants with RRMM in this study. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Overall Response Rate (ORR)
기간: Up to 52 months
|
Overall Response Rate is defined as the percentage of participants who achieve a partial response (PR) or better response according to the International Myeloma Working Group (IMWG) response criteria, as assessed by Response Review Committee (RRC). |
Up to 52 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Very Good Partial Response (VGPR) Rate
기간: Up to 52 months
|
VGPR rate is defined as the percentage of participants who achieve a VGPR or better response according to IMWG response criteria. |
Up to 52 months
|
|
Complete Response (CR) Rate
기간: Up to 52 months
|
CR rate is defined as the percentage of participants who achieve a CR or better response according to IMWG response criteria. |
Up to 52 months
|
|
Stringent Complete Response (sCR) Rate
기간: Up to 52 months
|
sCR rate is defined as the percentage of participants who achieve a sCR according to IMWG response criteria. |
Up to 52 months
|
|
Minimal Residual Disease (MRD) Negative Rate
기간: Up to 52 months
|
MRD negative rate is defined as the percentage of participants with negative MRD status according to IMWG response criteria. |
Up to 52 months
|
|
Clinical Benefit Rate (CBR)
기간: Up to 52 months
|
CBR is defined as the percentage of participants with clinical benefit. CBR=ORR (sCR + CR + VGPR + PR) + minimal response (MR). |
Up to 52 months
|
|
Duration of Response (DOR)
기간: Up to 52 months
|
DOR is defined as time from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease as defined in the IMWG criteria. |
Up to 52 months
|
|
Time to Response (TTR)
기간: Up to 52 months
|
TTR is defined as the time between the date of Day 1 of Cycle 1 and the first clinical response evaluation that the participant has met all criteria for PR or better response. |
Up to 52 months
|
|
Time to Best Response
기간: Up to 52 months
|
Time to best response is defined as the time between the date of Day 1 of Cycle 1 and best objective response. |
Up to 52 months
|
|
Time to Next Treatment (TTNT)
기간: Up to 52 months
|
TTNT is defined as the time from diagnosis to the start of the next-line treatment. |
Up to 52 months
|
|
Progression-free Survival (PFS)
기간: Up to 52 months
|
PFS is defined as the time from the date of Day 1 of Cycle 1 to the date of first documented disease progression (as defined in the IMWG response criteria) or death due to any cause, whichever occurs first. |
Up to 52 months
|
|
Time to Progression on the Next Line of Subsequent Antimyeloma Therapy or Death, Whichever Occurs First (PFS2)
기간: Up to 52 months
|
PFS2 is defined as the time from the date of Day 1 of Cycle 1 to progression on the next line of subsequent antimyeloma therapy or death, whichever occurs first. |
Up to 52 months
|
|
Overall Survival (OS)
기간: Up to 52 months
|
OS is the duration from the date of Day 1 of Cycle 1 to the date of the participant's death or study completion, whichever occurs first. |
Up to 52 months
|
|
Change from Baseline in Health-related Quality of Life (HRQoL) (Symptoms, Functioning, and Well-being) Assessed by European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC-QLQ-C30) Scale Score
기간: Baseline up to 52 months
|
The EORTC-QLQ-C30 Version 3 includes 30 items in 5 functional scales (physical, role, emotional, cognitive, and social), 1 global health status scale, 3 symptom scales (pain, fatigue, and nausea/vomiting), and 6 single symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The responses are reported using a verbal and numeric rating scales. The item and scale scores are transformed to a 0 to 100 scale. A high scale score represents a higher response level. Thus, a high score for a functional scale represents a high/healthy level of functioning and a high score for the global health status represents high HRQoL, but a high score for a symptom scale/item represents a high level of symptomatology/problems. |
Baseline up to 52 months
|
|
Change from Baseline in Health-related Quality of Life (HRQoL) (Symptoms, Functioning, and Well-being) Assessed by EuroQol Five Dimension Questionnaire 5-Level (EQ-5D-5L)
기간: Baseline up to 52 months
|
The EQ-5D-5L is a generic measure of health status. The EQ-5D-5L is a 5-item questionnaire that assesses 5 domains including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression plus a visual analog scale rating "health today" with anchors ranging from 0 (worst imaginable health state) to 100 (best imaginable health state). |
Baseline up to 52 months
|
|
Period 1 and 2: Change from Baseline in Health-related Quality of Life (HRQoL) (Symptoms, Functioning, and Well-being) Assessed by EORTC QLQ-IL39
기간: Baseline up to 52 months
|
EORTC QLQ-IL39 (four single items from the EORTC QLQMY20) will be performed to assess emotional health status (feel restless or agitated, thinking about your illness, worried about dying, worried about health in the future) on scale of 1 (not at all) to 4 (very much). |
Baseline up to 52 months
|
|
Number of Participants with Adverse Events (AEs)
기간: Up to 52 months
|
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. |
Up to 52 months
|
|
Severity of Adverse Events as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)
기간: Up to 52 months
|
Severity of AEs has 5 grades based on CTCAE criteria: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening consequences; Grade 5: Death related to adverse event. |
Up to 52 months
|
|
Period 3: Number of Participants Reporting Oral Toxicities Using Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
기간: Up to 52 months
|
PRO-CTCAE consist of 1-8 questions of common AEs experienced by people with cancer that are appropriate for self-reporting of treatment tolerability. Each symptom selected for inclusion can be rated by up to 3 attributes characterizing the presence/frequency, severity, and/or interference of the AEs. The following items were selected for inclusion for patients with multiple myeloma: nausea, vomiting, diarrhea, shortness of breath, rash, dizziness, headache, taste changes, and fatigue/tiredness/lack of energy. |
Up to 52 months
|
|
Period 3: Number of Participants Reporting Oral Toxicity Symptoms Using the Epstein Taste Survey (ETS)
기간: Up to 52 months
|
The Epstein Taste Survey consists of 17 items from the full 71 item PRO instrument, specific to taste changes. Developed for use in patients with head and neck cancer. |
Up to 52 months
|
|
Period 3: Percentage of Participants with Overall Response to Subsequent Therapies
기간: Up to 52 months
|
Overall Response Rate is defined as the percentage of participants who achieve a partial response (PR) or better response according to the International Myeloma Working Group (IMWG) response criteria, as assessed by Response Review Committee (RRC). Overall response for subsequent therapies, including BCMA-targeted therapies after treatment with talquetamab will be reported. |
Up to 52 months
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Janssen Pharmaceutica N.V., Belgium Clinical Trial, Janssen Pharmaceutica N.V., Belgium
간행물 및 유용한 링크
일반 간행물
- Einsele H, Moreau P, Bahlis N, Bhutani M, Vincent L, Karlin L, Perrot A, Goldschmidt H, van de Donk NWCJ, Ocio EM, Martinez-Lopez J, Rodriguez-Otero P, Dytfeld D, Diels J, Strulev V, Haddad I, Renaud T, Ammann E, Cabrieto J, Perualila N, Gan R, Zhang Y, Parekh T, Albrecht C, Weisel K, Mateos MV. Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma. Adv Ther. 2024 Apr;41(4):1576-1593. doi: 10.1007/s12325-024-02797-x. Epub 2024 Feb 24.
- Moreau P, Mateos MV, Gonzalez Garcia ME, Einsele H, De Stefano V, Karlin L, Lindsey-Hill J, Besemer B, Vincent L, Kirkpatrick S, Delforge M, Perrot A, van de Donk NWCJ, Pawlyn C, Manier S, Leleu X, Martinez-Lopez J, Ghilotti F, Diels J, Morano R, Albrecht C, Strulev V, Haddad I, Pei L, Kobos R, Smit J, Slavcev M, Marshall A, Weisel K. Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma. Adv Ther. 2024 Feb;41(2):696-715. doi: 10.1007/s12325-023-02738-0. Epub 2023 Dec 19.
- Einsele H, Moreau P, Bahlis N, Bhutani M, Vincent L, Karlin L, Perrot A, Goldschmidt H, van de Donk NWCJ, Ocio EM, Martinez Lopez J, Rodriguez-Otero P, Dytfeld D, Jakubowiak A, Schinke C, Besemer B, Anguille S, Manier S, Rasche L, Teipel R, Scheid C, Pawlyn C, Cavo M, Diels J, Ghilotti F, Lau BW, Renaud T, Orel O, Ong F, Ramos DF, Ammann E, Parekh T, Albrecht C, Weisel K, Mateos MV. Comparative Efficacy of Talquetamab vs. Real-World Physician's Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMent. Adv Ther. 2026 Jan;43(1):333-355. doi: 10.1007/s12325-025-03409-y. Epub 2025 Nov 28.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- CR109118
- 64407564MMY4001 (기타 식별자: Janssen Research & Development, LLC)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .